Cambridge Epigenetix’s pioneering TrueMethyl™ kit proves successful in beta trial

Cambridge Epigenetix Ltd. (CEGX), a leader in epigenetics tools innovation, today published the results of a successful beta trial evaluating their pioneering TrueMethyl™ oxidative bisulfite sequencing (oxBS-Seq) technology.

As a key step in the product validation process, 13 leading epigenetics labs in the United States, Europe and Japan were provided with TrueMethyl™ beta-kits for independent and rigorous testing using a shared panel of control samples. The participants selected represent a broad cross-section of labs leading a revolution in the understanding of epigenetic science and included:

• Professor Andy Feinberg - The Johns Hopkins University
• Dr George Vassiliou - The Wellcome Trust Sanger Institute
• Dr Nessa Carey- Neusentis-Pfizer Pharmaceutical Research Unit
• Professor Adrian Bird - The University of Edinburgh
• Professor Stephan Beck - University College London
• Professor Jonathan Mill –  University of Exeter & King's College London
• Professor Jörn Walter - Universität des Saarlandes
• Professor Wolf Reik and Dr Miguel Branco – The Babraham Institute
• Professor Hiro Sasaki - Kyushu University
• Dr Dirk Schübeler – Friedrich Miescher Institute for Biomedical Research
• Dr Skirmantas Kriaucionis – University of Oxford Ludwig Institute for Cancer Research
• Dr Marian Mellén - The Rockefeller University

The successful beta trial results demonstrate that TrueMethyl™’s innovative science and robust workflow deliver reliable and consistently high performance.  Dr George Vassiliou and Dr Malgorzata Gozdecka of the Wellcome Trust Sanger Institute said “We found the TrueMethyl kit a technically simple and rapid method for parallel genome-wide detection of cytosine methylation and hydroxy-methylation. Most importantly the kit, while being user friendly, enabled the generation of reliable and highly reproducible data sets.”

"The beta trial's success proves the accuracy and reproducibility across multiple labs of oxBS-Seq and was the final step in our rigorous development of commercial grade TrueMethyl™ kits” commented Dr Tony Smith, CTO of Cambridge Epigenetix.  “We are delighted at the level of demand at launch and expect TrueMethyl™ to become the industry standard."

CEGX’s application note (available for download at www.cambridge-epigenetix.com) describes the design of the international beta trial and summarizes the key results, illustrating the outstanding performance of TrueMethyl™ for quantitative detection and discrimination of cytosine, 5mC and 5hmC at single-base resolution.

To order TrueMethyl™ kits and learn more about the advantages of oxBS-Seq technology, please visit www.cambridge-epigenetix.com or email [email protected]